PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.10%
Negative revenue growth while AVGO stands at 9.07%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.45%
Negative gross profit growth while AVGO is at 21.83%. Joel Greenblatt would examine cost competitiveness or demand decline.
8.36%
EBIT growth below 50% of AVGO's 244.32%. Michael Burry would suspect deeper competitive or cost structure issues.
-5.45%
Negative operating income growth while AVGO is at 244.32%. Joel Greenblatt would press for urgent turnaround measures.
8.16%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
4.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
4.08%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.51%
Share reduction while AVGO is at 0.51%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.10%
Diluted share reduction more than 1.5x AVGO's 0.48%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
31.30%
Dividend growth above 1.5x AVGO's 0.44%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-1.84%
Negative OCF growth while AVGO is at 40.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.24%
FCF growth under 50% of AVGO's 58.55%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
45.31%
10Y revenue/share CAGR under 50% of AVGO's 397.51%. Michael Burry would suspect a lasting competitive disadvantage.
13.86%
5Y revenue/share CAGR under 50% of AVGO's 308.67%. Michael Burry would suspect a significant competitive gap or product weakness.
22.94%
3Y revenue/share CAGR under 50% of AVGO's 249.21%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
141.93%
10Y OCF/share CAGR under 50% of AVGO's 537.68%. Michael Burry would worry about a persistent underperformance in cash creation.
62.92%
Below 50% of AVGO's 326.80%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
26.13%
3Y OCF/share CAGR under 50% of AVGO's 297.38%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
131.02%
Positive 10Y CAGR while AVGO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
300.73%
Positive 5Y CAGR while AVGO is negative. John Neff might view this as a strong mid-term relative advantage.
123.41%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
35.88%
Below 50% of AVGO's 1202.31%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
9.07%
Below 50% of AVGO's 479.74%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
5.67%
Below 50% of AVGO's 307.90%. Michael Burry suspects a serious short-term disadvantage in building book value.
1168.08%
Dividend/share CAGR of 1168.08% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
194.90%
5Y dividend/share CAGR at 50-75% of AVGO's 385.62%. Martin Whitman might see a lagging policy in mid-term shareholder returns.
66.90%
3Y dividend/share CAGR at 50-75% of AVGO's 132.85%. Martin Whitman might see a weaker short-term approach to distributing cash.
-12.44%
Firm’s AR is declining while AVGO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.00%
Inventory is declining while AVGO stands at 7.20%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.33%
Asset growth above 1.5x AVGO's 0.43%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
2.34%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-0.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-2.83%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-7.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.